Edmund A Rossi

Summary

Country: USA

Publications

  1. ncbi The dock-and-lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures
    Edmund A Rossi
    IBC Pharmaceuticals, Inc, Morris Plains, New Jersey, USA
    Bioconjug Chem 23:309-23. 2012
  2. ncbi Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma
    Edmund A Rossi
    IBC Pharmaceuticals, Morris Plains, NJ 07950, USA
    Blood 113:6161-71. 2009
  3. ncbi CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas
    Edmund A Rossi
    Immunomedics Inc, Morris Plains, NJ 07950, USA
    Blood 114:3864-71. 2009
  4. ncbi Preclinical studies on targeted delivery of multiple IFN?2b to HLA-DR in diverse hematologic cancers
    Edmund A Rossi
    IBC Pharmaceuticals Inc, Morris Plains, NJ 07950, USA
    Blood 118:1877-84. 2011
  5. ncbi Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells
    Edmund A Rossi
    IBC Pharmaceuticals, Inc, Morris Plains, Jew Jersey, USA
    Clin Cancer Res 11:7122s-7129s. 2005
  6. ncbi A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma
    David V Gold
    Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey, USA
    Cancer Res 68:4819-26. 2008
  7. ncbi Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide
    William J McBride
    Immunomedics, Inc, Morris Plains, New Jersey, USA
    J Nucl Med 47:1678-88. 2006
  8. ncbi Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics
    Edmund A Rossi
    IBC Pharmaceuticals, Inc, USA
    Cancer Res 68:8384-92. 2008
  9. ncbi A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells
    Edmund A Rossi
    IBC Pharmaceuticals, Inc, Morris Plains, New Jersey, USA
    Cancer Res 70:7600-9. 2010
  10. ncbi A divalent hapten-peptide induces apoptosis in human non hodgkin lymphoma cell lines targeted by anti-CD20xanti-hapten bispecific antibodies
    Pierre Yves Brard
    Center for Molecular Medicine and Immunology, Belleville, New Jersey, 07109, USA
    Clin Cancer Res 13:5564s-5571s. 2007

Detail Information

Publications23

  1. ncbi The dock-and-lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures
    Edmund A Rossi
    IBC Pharmaceuticals, Inc, Morris Plains, New Jersey, USA
    Bioconjug Chem 23:309-23. 2012
    ..These achievements attest to the power of the DNL platform technology to develop novel therapeutic and diagnostic agents from both proteins and nonproteins for unmet medical needs...
  2. ncbi Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma
    Edmund A Rossi
    IBC Pharmaceuticals, Morris Plains, NJ 07950, USA
    Blood 113:6161-71. 2009
    ..These results indicate multiple advantages of hexavalent anti-CD20/22 bsAbs over the individual parental antibodies and suggest that these may represent a new class of cancer therapeutics...
  3. ncbi CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas
    Edmund A Rossi
    Immunomedics Inc, Morris Plains, NJ 07950, USA
    Blood 114:3864-71. 2009
    ..Targeting IFN-alpha with an anti-CD20 mAb makes the immunocytokine more potent than either agent alone. These findings suggest that 20-2b merits clinical evaluation as a new candidate antilymphoma therapeutic...
  4. ncbi Preclinical studies on targeted delivery of multiple IFN?2b to HLA-DR in diverse hematologic cancers
    Edmund A Rossi
    IBC Pharmaceuticals Inc, Morris Plains, NJ 07950, USA
    Blood 118:1877-84. 2011
    ..These results suggest that C2-2b-2b should be useful in the treatment of various hematopoietic malignancies...
  5. ncbi Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells
    Edmund A Rossi
    IBC Pharmaceuticals, Inc, Morris Plains, Jew Jersey, USA
    Clin Cancer Res 11:7122s-7129s. 2005
    ..CONCLUSIONS: The results indicate that hBS14 is an attractive candidate for use in a variety of pretargeting applications, particularly tumor therapy with radionuclides and drugs...
  6. ncbi A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma
    David V Gold
    Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey, USA
    Cancer Res 68:4819-26. 2008
    ..Thus, the results suggest that TF10 pretargeting may provide improved imaging for early detection, diagnosis, and treatment of pancreatic cancer as compared with directly radiolabeled PAM4-IgG...
  7. ncbi Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide
    William J McBride
    Immunomedics, Inc, Morris Plains, New Jersey, USA
    J Nucl Med 47:1678-88. 2006
    ....
  8. ncbi Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics
    Edmund A Rossi
    IBC Pharmaceuticals, Inc, USA
    Cancer Res 68:8384-92. 2008
    ....
  9. ncbi A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells
    Edmund A Rossi
    IBC Pharmaceuticals, Inc, Morris Plains, New Jersey, USA
    Cancer Res 70:7600-9. 2010
    ..Our findings indicate that a given cell's responsiveness to MAb-IFN? depends on its sensitivity to IFN? and the specific antibodies, as well as the expression and density of the targeted antigens...
  10. ncbi A divalent hapten-peptide induces apoptosis in human non hodgkin lymphoma cell lines targeted by anti-CD20xanti-hapten bispecific antibodies
    Pierre Yves Brard
    Center for Molecular Medicine and Immunology, Belleville, New Jersey, 07109, USA
    Clin Cancer Res 13:5564s-5571s. 2007
    ..The goal of this study was to determine if a divalent hapten-peptide could induce apoptosis by cross-linking bsMAb bound to CD20...
  11. ncbi Improved 18F labeling of peptides with a fluoride-aluminum-chelate complex
    William J McBride
    Immunomedics, Inc, Morris Plains, New Jersey 07950, USA
    Bioconjug Chem 21:1331-40. 2010
    ..The IMP467 peptide could be labeled up to 115 GBq/micromol (3100 Ci/mmol), with a total reaction and purification time of 30 min without chromatographic purification...
  12. ncbi Bispecific antibody pretargeting of radionuclides for immuno single-photon emission computed tomography and immuno positron emission tomography molecular imaging: an update
    Robert M Sharkey
    Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey, USA
    Clin Cancer Res 13:5577s-5585s. 2007
    ..Thus, this bispecific antibody pretargeting procedure may contribute to tumor detection and could also contribute to the detection of other diseases having distinct antigen targets and suitably specific antibodies...
  13. ncbi A new method to produce monoPEGylated dimeric cytokines shown with human interferon-?2b
    Chien Hsing Chang
    IBC Pharmaceuticals Inc, Morris Plains, New Jersey 07950, USA
    Bioconjug Chem 20:1899-907. 2009
    ..We anticipate wide applicability of the DNL method for developing long-acting therapeutics that are dimeric and monoPEGylated with the increased bioavailability allowing for less frequent dosing...
  14. ncbi Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias
    Pankaj Gupta
    Immunomedics Inc, Morris Plains, NJ, USA
    Blood 116:3258-67. 2010
    ....
  15. ncbi A novel method of 18F radiolabeling for PET
    William J McBride
    Immunomedics, Inc, 300 American Way, Morris Plains, NJ 07950, USA
    J Nucl Med 50:991-8. 2009
    ..We report a facile method wherein (18)F is first attached to aluminum as Al(18)F, which is then bound to a chelate attached to a peptide, forming a stable Al(18)F-chelate-peptide complex in an efficient 1-pot process...
  16. ncbi Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates
    Gary L Griffiths
    Immunomedics, Inc, Morris Plains, New Jersey Garden State Cancer Center, Belleville, New Jersey 07950, USA
    J Nucl Med 45:30-9. 2004
    ..The aim of this work was to develop reagents and methods potentially useful in PET, using (68)Ga in a 2-step pretargeting protocol...
  17. ncbi Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting
    Edmund A Rossi
    IBC Pharmaceuticals, Inc, 300 American Road, Morris Plains, NJ 07950, USA
    Proc Natl Acad Sci U S A 103:6841-6. 2006
    ....
  18. ncbi Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy
    Edmund A Rossi
    IBC Pharmaceuticals, Inc, Morris Plains, New Jersey 07950, USA
    Clin Cancer Res 9:3886S-96S. 2003
    ..BS6 and BS8 may be even more attractive because of their potential to achieve higher levels of tumor uptake because of divalent carcinoembryonic antigen binding...
  19. ncbi Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies
    Robert M Sharkey
    Center for Molecular Medicine and Immunology CMMI, Belleville, New Jersey, USA
    Cancer Biother Radiopharm 25:1-12. 2010
    ..Thus, DNL technology is a highly flexible platform that can be used to prepare many different types of agents that could further improve cancer detection and therapy...
  20. ncbi The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity
    Chien Hsing Chang
    Immunomedics, Inc, Morris Plains, NJ 07950, USA
    Clin Cancer Res 13:5586s-5591s. 2007
    ....
  21. ncbi Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas
    Pankaj Gupta
    Immunomedics Inc, Morris Plains, NJ
    Blood 119:3767-78. 2012
    ..Such bispecific HexAbs may constitute a new class of therapeutic agents for improved cancer immunotherapy, as shown here for MCL and other CD20(+)/CD74(+) malignancies...
  22. ncbi A new mammalian host cell with enhanced survival enables completely serum-free development of high-level protein production cell lines
    Diane L Rossi
    Immunomedics, Inc, Morris Plains, NJ 07950, USA
    Biotechnol Prog 27:766-75. 2011
    ....
  23. ncbi Molecular advances in pretargeting radioimunotherapy with bispecific antibodies
    Chien-Hsing Chang
    IBC Pharmaceuticals, L. L. C, Morris Plains, New Jersey 07950, USA
    Mol Cancer Ther 1:553-63. 2002
    ..In addition, both preclinical and clinical results obtained from a pretargeting method known as the Affinity Enhancement System are presented. Future directions of pretargeting technology are also suggested...